NCT06706973 Profiling and Targeting Epigenetic Marks to Improve Diagnosis and Therapeutic Approaches in Head and Neck Cancer
| NCT ID | NCT06706973 |
| Status | Recruiting |
| Phase | — |
| Sponsor | European Institute of Oncology |
| Condition | Head and Neck Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-03-06 |
| Primary Completion | 2030-04-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2024-03-06 with a primary completion date of 2030-04-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Investigators have recently shown that epigenetic remodelling enzymes, such as HDAC inhibitors, are feasible drugs in HNC (8, 9). Preliminary data are indicating some deregulated epigenetics marks suggesting the corresponding histone modifiers as possible targets for the treatment of HNC, providing an attractive and feasible option to build upon. Our overarching hypothesis is that unique histone marks distinguish HPV+ and HPV- HNC and that specific histone modifiers are novel mediators of HNC tumorigenesis in an HPV specific manner
Eligibility Criteria
Inclusion Criteria:• Age: Adults aged ≥ 18 years diagnosed with HNC * Sex: Both male and female * Human papilloma virus (HPV) test: Both positive and negative. * Tumor: primary tumors, treatment naïve, squamous cell carcinoma * Cancer stage: I-IV * Anatomic location: oral cavity, larynx, oropharynx * Tumor fragments not required for diagnostics Exclusion Criteria: * Previous radiotherapy, chemotherapy or immunotherapy for HNC * Unable to provide written informed consent
Contact & Investigator
Susanna Chiocca
PRINCIPAL INVESTIGATOR
Istituto Europeo di Oncologia
Frequently Asked Questions
Who can join the NCT06706973 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Head and Neck Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06706973 currently recruiting?
Yes, NCT06706973 is actively recruiting participants. Contact the research team at susanna.chiocca@ieo.it for enrollment information.
Where is the NCT06706973 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT06706973 clinical trial?
NCT06706973 is sponsored by European Institute of Oncology. The principal investigator is Susanna Chiocca at Istituto Europeo di Oncologia. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.